Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group

International Journal of Hematology

Volumn 96, Issue 2, 2012, Pages 171-177

  Miyawaki, Shuichi ^a  

^a Tokyo Metropolitan Ohtsuka Hospital   (Japan)

Author keywords

AML; Clinical study; JALSG; Prognostic factor

Indexed keywords

ANTHRACYCLINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAPAN; LONG TERM CARE; MORTALITY; OVERALL SURVIVAL; QUALITY OF LIFE;

CONSOLIDATION CHEMOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; JAPAN; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; PROGNOSIS; SALVAGE THERAPY;

EID: 84866989931     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1150-6     Document Type: Article

References (32)

1. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-7.
2. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-51.
3. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-74.
4. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-9.
5. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin with in acute myeloid leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992;10:1103-8.
6. The AML collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction for acute myeloid leukemia. Br J Haematol. 1998;103:100-9.
7. Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, et al. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol. 2010;91:276-83.
8. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer. 2005;104:2726-34.
9. Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance intensification therapy between 4 or 12 courses in adult acute myeloid leukemia: AML- 87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71:3888-95.
10. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. J Clin Oncol. 1996;14:204-13.
11. Miyawaki S, Tanimoto M, Kobayashi T, Kuriyama K, Murakami H, Yoshida M, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Int J Hematol. 1999;70: 97-104.
12. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard- dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSGAML201 Study. Blood. 2011;117:1613-8.
13. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361:1249-59.
14. Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita Hi, Kiyoi H, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci. 2011;102:1358-65.
15. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379: 1508-16.
16. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994; 331(14):896-903.
17. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of highdose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117: 2366-72.
18. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339(23):1649-56.
19. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90:2978-86.
20. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-400.
21. Keating S, de Witte T, Suciu S, et al. The influence of HLA matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1998;102(5):1344-53.
22. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol. 2010;91:284-92.
23. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-50.
24. Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, et al. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol. 2007;86:343-7.
25. Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, et al. Phase II Study of FLAGM (fludarabine ? high-dose cytarabine ? granulocyte colony-stimulating factor ? mitoxantrone) for relapsed or refractory acute myeloid leukemia: Recommendable salvage therapy for subsequent stem cell transplantation. Leuk Lymphoma. 2012 Submitted.
26. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-83.
27. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-33.
28. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-18.
29. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-80.
30. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.
31. Kuriyama K, Tomonaga M, Kobayashi T, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. In: Hiddeman W, Buchner T, Worman B, et al., editors. Acute leukemias VII: experimental approaches and novel therapies. New York: Springer; 1998. p. 901-905.
32. Miyazaki Y, Nishida K, Kuriyama K, Taniwaki M, Sakamaki H, Miyawaki S, et al. A new scoring system to predict the prognosis of patients with acute myeloid leukemia. study from the Japan Adult Leukemia Study Group. Blood. 2005;106:667a. Abstract 2373.